agennix, rh-lactoferrin, lactoferrin, oncology, baylor medical college, houston-based biopharmaceutical, recombinant lactoferrin, rhlf, cancer, oncology, wound, wound healing, immunity, immunology, immune system, anti-inflammatory, immuno-stimulatory, biopharmaceutical, clinical research, clinical trials, research, preclinical, manufacturing, biotech, biotechnology, patents, drug

agennix, world leader in the development of recombinant human lactoferrin (rhlf), is a biopharmaceutical company focused on developing protein-based drugs for oncology and wound healing.